Controlling the kinetics of interferon transgene expression for improved gene therapy

References

• Ando M, Takahashi Y, Nishikawa M, Watanabe Y, Takakura Y. (2012). Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy. J Gene Med, 14, 288–295.
   PubMed Web of Science ®Google Scholar
• Argyros O, Wong SP, Fedonidis C, Tolmachov O, Waddington SN, Howe SJ, Niceta M, Coutelle C, Harbottle RP. (2011). Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med, 89, 515–529.
   PubMed Web of Science ®Google Scholar
• Bracarda S, Eggermont AM, Samuelsson J. (2010). Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer, 46, 284–297.
   PubMed Web of Science ®Google Scholar
• Chen ZY, He CY, Ehrhardt A, Kay MA. (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther, 8, 495–500.
   PubMed Web of Science ®Google Scholar
• Chen ZY, He CY, Meuse L, Kay MA. (2004). Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther, 11, 856–864.
   PubMed Web of Science ®Google Scholar
• Chen ZY, Riu E, He CY, Xu H, Kay MA. (2008). Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther, 16, 548–556.
   PubMed Web of Science ®Google Scholar
• Edelstein M. (2012). Gene therapy clinical trials worldwide [Online]. John Wiley and Sons Ltd. Available: http://www.wiley.com/legacy/wileychi/genmed/clinical/ [Accessed 24 April 2012].
   Google Scholar
• Edelstein ML, Abedi MR, Wixon J. (2007). Gene therapy clinical trials worldwide to 2007–an update. J Gene Med, 9, 833–842.
   PubMed Web of Science ®Google Scholar
• Edelstein ML, Abedi MR, Wixon J, Edelstein RM. (2004). Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med, 6, 597–602.
   PubMed Web of Science ®Google Scholar
• Harkins RN, Szymanski P, Petry H, Brooks A, Qian HS, Schaefer C, Kretschmer PJ, Orme A, Wang P, Rubanyi GM, Hermiston TW. (2008). Regulated expression of the interferon-beta gene in mice. Gene Ther, 15, 1–11.
   PubMed Web of Science ®Google Scholar
• Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. (2010). Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol, 184, 2729–2735.
   PubMed Web of Science ®Google Scholar
• Huang M, Chen Z, Hu S, Jia F, Li Z, Hoyt G, Robbins RC, Kay MA, Wu JC. (2009). Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation, 120, S230–S237.
   PubMed Web of Science ®Google Scholar
• Kalanjeri S, Sterman D. (2012). Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies. Curr Resp Care Rep, 1, 54–66.
   Google Scholar
• Kamimura K, Suda T, Zhang G, Liu D. (2011). Advances in Gene Delivery Systems. Pharmaceut Med, 25, 293–306.
   PubMedGoogle Scholar
• Kawano H, Nishikawa M, Mitsui M, Takahashi Y, Kako K, Yamaoka K, Watanabe Y, Takakura Y. (2007). Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int J Cancer, 121, 401–406.
   PubMed Web of Science ®Google Scholar
• Kreiss P, Cameron B, Rangara R, Mailhe P, Aguerre-Charriol O, Airiau M, Scherman D, Crouzet J, Pitard B. (1999). Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res, 27, 3792–3798.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang F, Xu S, Fire AZ, Kay MA. (2012). The extragenic spacer length between the 5′ and 3′ ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther. DOI: 10.1038/mt.2012.65.
   Google Scholar
• Magnusson T, Haase R, Schleef M, Wagner E, Ogris M. (2011). Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. J Gene Med, 13, 382–391.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S, Yasue S, Sakakibara A, Tomita Y, Kageshita T, Kawakami Y, Mizuno M, Yoshida J, Saida T. (2008). A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol, 38, 849–856.
   PubMed Web of Science ®Google Scholar
• Mayrhofer P, Schleef M, Jechlinger W. (2009). Use of minicircle plasmids for gene therapy. Methods Mol Biol, 542, 87–104.
   PubMedGoogle Scholar
• Mehier-Humbert S, Guy RH. (2005). Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev, 57, 733–753.
   PubMed Web of Science ®Google Scholar
• Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, Watanabe Y, Takakura Y. (2009). Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med, 11, 435–443.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Hashida M. (2002). Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull, 25, 275–283.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Huang L. (2001). Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther, 12, 861–870.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Nakayama A, Takahashi Y, Fukuhara Y, Takakura Y. (2008). Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum Gene Ther, 19, 1009–1020.
   PubMed Web of Science ®Google Scholar
• Nordstrom JL. (2003). The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids, 68, 1085–1094.
   PubMed Web of Science ®Google Scholar
• Platanias LC. (2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 5, 375–386.
   PubMed Web of Science ®Google Scholar
• Raab-Traub N. (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol, 12, 431–441.
   PubMed Web of Science ®Google Scholar
• Riu E, Grimm D, Huang Z, Kay MA. (2005). Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum Gene Ther, 16, 558–570.
   PubMed Web of Science ®Google Scholar
• Sadler AJ, Williams BR. (2008). Interferon-inducible antiviral effectors. Nat Rev Immunol, 8, 559–568.
   PubMed Web of Science ®Google Scholar
• Scheule RK. (2000). The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev, 44, 119–134.
   PubMed Web of Science ®Google Scholar
• Szymanski P, Kretschmer PJ, Bauzon M, Jin F, Qian HS, Rubanyi GM, Harkins RN, Hermiston TW. (2007). Development and validation of a robust and versatile one-plasmid regulated gene expression system. Mol Ther, 15, 1340–1347.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Nishikawa M, Takakura Y. (2012). Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front Biosci (Schol Ed), 4, 133–141.
   PubMedGoogle Scholar
• van Gaal EV, Hennink WE, Crommelin DJ, Mastrobattista E. (2006). Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy. Pharm Res, 23, 1053–1074.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J. (2008). A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med, 10, 329–339.
   PubMed Web of Science ®Google Scholar
• Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W. (2006). Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res, 12, 4702–4713.
   PubMed Web of Science ®Google Scholar
• Yates JL, Camiolo SM, Bashaw JM. (2000). The minimal replicator of Epstein-Barr virus oriP. J Virol, 74, 4512–4522.
   PubMed Web of Science ®Google Scholar
• Yew NS. (2005). Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev, 57, 769–780.
   PubMed Web of Science ®Google Scholar
• Yew NS, Cheng SH. (2004). Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv, 1, 115–125.
   PubMedGoogle Scholar
• Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH. (2002). CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther, 5, 731–738.
   PubMed Web of Science ®Google Scholar
• Yin W, Xiang P, Li Q. (2005). Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem, 346, 289–294.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Wu J, Xu Z, Yang S, Yan H, Tan L, Meng X, Ying X, Liu R, Kang T, Huang W. (2011). Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS ONE, 6, e19407.
   PubMed Web of Science ®Google Scholar